JP2022501357A5 - - Google Patents

Info

Publication number
JP2022501357A5
JP2022501357A5 JP2021515172A JP2021515172A JP2022501357A5 JP 2022501357 A5 JP2022501357 A5 JP 2022501357A5 JP 2021515172 A JP2021515172 A JP 2021515172A JP 2021515172 A JP2021515172 A JP 2021515172A JP 2022501357 A5 JP2022501357 A5 JP 2022501357A5
Authority
JP
Japan
Prior art keywords
antibody
elution buffer
multispecific
binding
concentration
Prior art date
Application number
JP2021515172A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020061478A5 (https=
JP2022501357A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/052199 external-priority patent/WO2020061478A2/en
Publication of JP2022501357A publication Critical patent/JP2022501357A/ja
Publication of JP2022501357A5 publication Critical patent/JP2022501357A5/ja
Publication of JPWO2020061478A5 publication Critical patent/JPWO2020061478A5/ja
Priority to JP2024065251A priority Critical patent/JP2024099610A/ja
Pending legal-status Critical Current

Links

JP2021515172A 2018-09-21 2019-09-20 ヘテロ二量体多重特異性抗体を精製するための方法 Pending JP2022501357A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024065251A JP2024099610A (ja) 2018-09-21 2024-04-15 ヘテロ二量体多重特異性抗体を精製するための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862734566P 2018-09-21 2018-09-21
US62/734,566 2018-09-21
US201862742821P 2018-10-08 2018-10-08
US62/742,821 2018-10-08
PCT/US2019/052199 WO2020061478A2 (en) 2018-09-21 2019-09-20 Methods for purifying heterodimeric, multispecific antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024065251A Division JP2024099610A (ja) 2018-09-21 2024-04-15 ヘテロ二量体多重特異性抗体を精製するための方法

Publications (3)

Publication Number Publication Date
JP2022501357A JP2022501357A (ja) 2022-01-06
JP2022501357A5 true JP2022501357A5 (https=) 2022-09-29
JPWO2020061478A5 JPWO2020061478A5 (https=) 2022-09-29

Family

ID=68240802

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021515172A Pending JP2022501357A (ja) 2018-09-21 2019-09-20 ヘテロ二量体多重特異性抗体を精製するための方法
JP2024065251A Pending JP2024099610A (ja) 2018-09-21 2024-04-15 ヘテロ二量体多重特異性抗体を精製するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024065251A Pending JP2024099610A (ja) 2018-09-21 2024-04-15 ヘテロ二量体多重特異性抗体を精製するための方法

Country Status (11)

Country Link
US (2) US20210355215A1 (https=)
EP (1) EP3853253A2 (https=)
JP (2) JP2022501357A (https=)
KR (1) KR20210063354A (https=)
CN (1) CN112839959A (https=)
BR (1) BR112021004680A2 (https=)
CA (1) CA3113057A1 (https=)
IL (1) IL281570A (https=)
MX (1) MX2021003169A (https=)
SG (1) SG11202102713TA (https=)
WO (1) WO2020061478A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3029209A1 (en) 2016-06-21 2017-12-28 Teneobio, Inc. Cd3 binding antibodies
IL264941B2 (en) 2016-08-24 2025-12-01 Teneobio Inc Transgenic non-human animals producing modified heavy chain-only antibodies
FI4050034T3 (fi) * 2016-09-14 2024-06-10 Teneoone Inc Cd3:een sitoutuvia vasta-aineita
NZ754713A (en) 2016-12-21 2025-11-28 Teneobio Inc Anti-bcma heavy chain-only antibodies
US11427642B2 (en) 2017-06-20 2022-08-30 Teneoone, Inc. Anti-BCMA heavy chain-only antibodies
WO2019126756A1 (en) 2017-12-22 2019-06-27 Teneobio, Inc. Heavy chain antibodies binding to cd22
JP7776987B2 (ja) 2019-04-05 2025-11-27 テネオバイオ， インコーポレイテッド Ｐｓｍａに結合する重鎖抗体
CN114206927B (zh) 2019-06-14 2025-03-21 特尼奥生物股份有限公司 与cd22和cd3结合的多特异性重链抗体
KR102153258B1 (ko) * 2020-02-21 2020-09-07 프레스티지바이오로직스 주식회사 베바시주맙 정제의 최적화된 방법
TWI838621B (zh) * 2020-04-29 2024-04-11 美商泰尼歐萬公司 具有經修飾重鏈恆定區之多特異性重鏈抗體
AU2021263448B2 (en) * 2020-04-29 2026-02-05 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
KR102744698B1 (ko) * 2020-04-29 2024-12-24 테네오원, 인코포레이티드 변형된 중쇄 불변 영역을 갖는 다중특이적 중쇄 항체
CN114539417A (zh) * 2020-11-26 2022-05-27 盛禾(中国)生物制药有限公司 一种有效去除双特异性抗体同源二聚体的层析纯化工艺
WO2022222949A1 (zh) * 2021-04-23 2022-10-27 和铂医药(上海)有限责任公司 一种双特异性抗体的纯化方法
WO2025251034A1 (en) * 2024-05-31 2025-12-04 Amgen Inc. Purification method

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
DE19836213A1 (de) * 1998-08-11 2000-02-24 Gerhard Harry Scholz Verfahren zur Elution von Biomolekülen von Chromatographie-Materialien
CA2410551A1 (en) * 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Heterodimeric fusion proteins
WO2004042017A2 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
CA2513113A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
US20080286819A1 (en) 2005-11-07 2008-11-20 Ravetch Jeffrey V Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
MX2008012843A (es) 2006-04-05 2009-01-19 Univ Rockefeller Polipeptidos con propiedades antiinflamatorias aumentadas y citotoxicas reducidas y metodos relacionados.
LT3660032T (lt) * 2009-06-25 2026-02-25 Amgen Inc. Ne žinduolių sistemoje ekspresuotų baltymų surišamojo gryninimo būdai
JP2014515598A (ja) * 2011-03-10 2014-07-03 エイチシーオー アンティボディ， インク． 二重特異性三鎖抗体様分子
PT2825559T (pt) * 2012-03-13 2019-06-07 Novimmune Sa Anticorpos biespecíficos prontamente isolados com formato de imunoglobulina nativo
US11261262B2 (en) * 2013-09-03 2022-03-01 Novimmune Sa Readily isolated bispecific binding molecules with native format having mutated constant regions
ES2936810T3 (es) * 2014-05-16 2023-03-22 Pfizer Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería
AR101262A1 (es) * 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
AU2016245887B2 (en) * 2015-04-10 2021-09-23 Adimab, Llc. Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
CN107446044B (zh) * 2016-05-30 2021-04-30 越海百奥药业(绍兴)有限公司 一种纯化抗体的方法及所用缓冲液
CA3218290A1 (en) * 2016-07-22 2018-01-25 Amgen Inc. Methods of purifying fc-containing proteins
NZ754713A (en) 2016-12-21 2025-11-28 Teneobio Inc Anti-bcma heavy chain-only antibodies
WO2019183406A1 (en) * 2018-03-21 2019-09-26 Invenra Inc. Multispecific antibody purification with ch1 resin

Similar Documents

Publication Publication Date Title
US20250197497A1 (en) Methods for purifying heterodimeric, multispecific antibodies
JP2022501357A5 (https=)
US20230220081A1 (en) BISPECIFIC HETERODIMERIC FUSION PROTEINS CONTAINING IL-15 - IL-15Ralpha Fc-FUSION PROTEINS AND IMMUNE CHECKPOINT ANTIBODY FRAGMENTS
RU2606264C2 (ru) Способ полипептидной модификации для очистки полипептидных мультимеров
US10363496B2 (en) Method for purification of monoclonal antibodies
WO2021026387A2 (en) HETERODIMERIC IgG-LIKE BISPECIFIC ANTIBODIES
KR20210003814A (ko) IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
CN1810292A (zh) 用离子交换层析纯化蛋白质
JPWO2020061478A5 (https=)
US20220227867A1 (en) ICOS TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND ICOS ANTIGEN BINDING DOMAINS
US12247065B2 (en) Method for producing a controlled mixture of two or more different antibodies
JP2011500757A (ja) Ｆｃ含有タンパク質の精製方法
US20250243275A1 (en) Multi-domain binding molecules
RU2820588C2 (ru) Способы очистки гетеродимерных полиспецифических антител
AU2019343053B2 (en) Methods for purifying heterodimeric, multispecific antibodies
US20250340613A1 (en) Bispecific antibody comprising a heterodimer based on mhc proteins
WO2026078029A1 (en) Splitted interleukin-2 prodrugs and uses thereof
OA21635A (en) Bispecific Antibody Comprising A Heterodimer Based On Mhc Proteins.
WO2025094054A1 (en) Method for purifying small multi-domain proteins